-
DPI-289, a Novel Bi-Functional Delta Agonist / Mu Antagonist (DAMA) as a Therapy for Parkinson's Disease
… treatment, thus delaying the onset of sensitization and dyskinesia. Project Description: This project has been … and the potential risk that a DAMA compound may elicit dyskinesia in a pre-clinical model of PD. If findings show …
-
Global Charities Join Forces to Drive Forward New Drug for Parkinson’s
November 23, 2020
… Neurolixis joint funding to test a new drug to reduce dyskinesia in people with Parkinson’s New drug holds potential to reduce dyskinesia, a common side effect of current Parkinson’s …
-
Michael J. Fox Foundation Awards $3 Million to Push Eight Industry Parkinson's Drug Development Projects Toward Commercialization
July 1, 2010
… Current Therapies Flibanserin in Levodopa-induced Dyskinesia: MPTP-lesioned Pre-clinical Model Jurgen Beck, … Receptor Antagonists for the Treatment of Levodopa-induced Dyskinesias in Parkinson’s Disease (Supplemental Award) …
-
Addex and MJFF Announce Next Step for Dipra
March 19, 2013
… of dipraglurant, or “dipra,” for the treatment of dyskinesia, the debilitating side effect of long-term … fund continued human clinical testing of dipraglurant. “Dyskinesia is a top priority for our Foundation because of …
-
Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's Disease
… side effects including abnormal involuntary movements, or dyskinesias. There is therefore a continual search for novel …
-
Modulation of Glycine for the Treatment of Parkinson’s Disease
… development of uncontrollable involuntary movements, called dyskinesia. In addition, the benefits conferred by levodopa … adequately address the symptoms of PD without exacerbating dyskinesia. Many people with advanced PD also experience …